OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy volunteers vaccinated. Promising preclinical efficacy signals guide development